Equities Analysts Offer Predictions for Masimo Q1 Earnings

Masimo Co. (NASDAQ:MASI) – Investment analysts at Zacks Research upped their Q1 2025 EPS estimates for Masimo in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical equipment provider will earn $0.91 per share for the quarter, up from their previous forecast of $0.89. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q3 2025 earnings at $1.01 EPS, Q4 2025 earnings at $1.34 EPS, FY2025 earnings at $4.25 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.45 EPS and FY2026 earnings at $4.89 EPS.

Other equities analysts have also issued research reports about the stock. Raymond James boosted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler boosted their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Wells Fargo & Company boosted their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Stock Performance

NASDAQ:MASI opened at $177.21 on Friday. The firm has a 50 day simple moving average of $172.90 and a 200-day simple moving average of $151.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm has a market cap of $9.49 billion, a PE ratio of 122.21 and a beta of 1.02. Masimo has a 1-year low of $101.61 and a 1-year high of $184.51.

Hedge Funds Weigh In On Masimo

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp acquired a new position in Masimo during the fourth quarter worth approximately $27,000. UMB Bank n.a. increased its position in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 123 shares in the last quarter. Trust Co. of Vermont acquired a new stake in shares of Masimo in the fourth quarter worth $33,000. Blue Trust Inc. increased its position in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.